Pinc PeptideThe girly peptide research blog

Survodutide · Dose evidence · updated 8 October 2026

Survodutide dosage: what studies actually used

The short answer

No dose of survodutide is approved, because no regulator has approved it as of 7 October 202612. In the phase 3 SYNCHRONIZE trials, the dose was raised step by step to a target of 3.6 mg or 6.0 mg once a week, injected under the skin, over 76 weeks34. This page reports trial doses and is not dosing advice. Vials sold online are another matter: of the 27 survodutide tests Finnrick listed from April 2025 to April 2026, 13 failed and 1 was incomplete5.

Not dosing advice. This page reports doses that studies and approved labels used, with their sources. It does not recommend a dose, and we do not give mixing, injection or unit-conversion instructions. Gray-market vials often do not contain what their label says. How we report doses.

Every dose studied in people

StudyWhoPeopleDose and routeWhat happened
SYNCHRONIZE-2 (Wharton 2026), randomized trial Adults with type 2 diabetes and a BMI of 27 or more 752 3.6 or 6.0 mg once a week
Injection under the skin · 76 weeks		 Weight fell 8.2% and 9.8%, versus 3.9% on placebo4; 18% on survodutide versus 1.2% on placebo stopped because of digestive side effects1.
SYNCHRONIZE-1 (le Roux 2026), randomized trial Adults with obesity, or overweight with a weight-related condition, without diabetes 725 Adjusted up to 3.6 or 6.0 mg once a week
Injection under the skin · 76 weeks		 Weight fell 12.2% and 13.0%, versus 5.4% on placebo3; digestive side effects led 17.8% and 20.2% to stop, versus 2.9%6.
Phase 2 trial in type 2 diabetes (Blüher 2024), randomized trial Adults with type 2 diabetes on metformin 413 Up to 0.3, 0.9, 1.8 or 2.7 mg once a week, or 1.2 or 1.8 mg twice a week, versus placebo or semaglutide up to 1.0 mg once a week
Injection under the skin · 16 weeks		 HbA1c fell by up to 1.71 points, and weight by up to 8.7% on 1.8 mg twice a week, versus 5.3% on semaglutide; side effects affected 77.8% on survodutide, versus 52.5% on placebo7.
Phase 2 obesity trial (le Roux 2024), randomized trial Adults with a BMI of 27 or more, without diabetes 387 0.6, 2.4, 3.6 or 4.8 mg once a week
Injection under the skin · 46 weeks: 20 of step-up, 26 of maintenance		 By assigned dose, weight fell 6.2%, 12.5%, 13.2% and 14.9%, versus 2.8% on placebo; digestive side effects affected 75% versus 42%8.
Phase 2 MASH trial (Sanyal 2024), randomized trial Adults with MASH (fatty liver disease with inflammation) and fibrosis stage F1 to F3 293 2.4, 4.8 or 6.0 mg once a week
Injection under the skin · 48 weeks: 24 of fast step-up, 24 of maintenance		 MASH improved without worse fibrosis in 47%, 62% and 43%, versus 14% on placebo; nausea affected 66% versus 23%9.
SYNCHRONIZE-MASLD (Kaplan 2026), randomized trial Adults with obesity and fatty liver disease with signs of inflammation or scarring 216 6.0 mg once a week
Injection under the skin · 48 weeks		 Liver fat fell by 30% or more in 68.5% versus 28.6% on placebo; digestive side effects led 19.9% versus 4.3% to stop10.
Phase 1b trial (Jungnik 2023), randomized trial Adults with a BMI of 27 to 40 125 Rising weekly doses, stepped up over 6 weeks (Part A) or 16 weeks (Part B)
Injection under the skin · Doses raised over 6 or 16 weeks		 Weight fell by up to 13.8% more than on placebo by week 16 in Part B; 12.5% in Part A and 17.8% in Part B stopped treatment early11.

Studies, animals and users: kept apart

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

No dose is approved. In the Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials, the dose was raised gradually to a target of 3.6 mg or 6.0 mg once weekly, injected under the skin, for 76 weeks in total34. SYNCHRONIZE-MASLD used 6.0 mg weekly for 48 weeks10. The Phase 2 obesity trial tested 0.6, 2.4, 3.6 and 4.8 mg weekly over 46 weeks8, and the Phase 2 MASH trial tested 2.4, 4.8 and 6.0 mg weekly over 48 weeks9. A 16-week Phase 2 trial in type 2 diabetes tested doses up to 2.7 mg weekly or 1.8 mg twice weekly7.

In animal studies

Mice: diet-induced obese male mice received daily injections under the skin of 3, 10, 20 or 30 nmol/kg for 30 days, compared with semaglutide at 20 or 100 nmol/kg12. These are research doses in animals, not human doses.

What users report

No community dosing page was cited for this compound.

Half-life and how it is taken

Routes
  • Subcutaneous injection once weekly (one Phase 2 trial also tested twice weekly); the only route in the human studies we found
  • No human data found for any other route

Why the dose goes up slowly

In SYNCHRONIZE-1 and SYNCHRONIZE-MASLD, digestive side effects were most common while the dose was going up610. In SYNCHRONIZE-1, they led 17.8% of people on 3.6 mg and 20.2% on 6.0 mg to stop, versus 2.9% on placebo6. In SYNCHRONIZE-2, 18% on survodutide stopped because of them, versus 1.2% on placebo1. Boehringer Ingelheim says these stops usually came during the step-up phase, as the trial protocol allowed limited flexibility to manage side effects, and that current and upcoming trials allow more flexible step-ups1.

Earlier trials used different paces8911. In phase 1, weekly doses were raised over 6 weeks in one part and over 16 weeks in another11. The phase 2 obesity trial used 20 weeks of step-up before 26 weeks of maintenance, and the phase 2 MASH trial a fast 24-week step-up before 24 weeks of maintenance89.

Why each phase 3 trial reports two results

Phase 3 results come in two versions36. The treatment-regimen analysis includes the effects of stopping early, using obesity drugs the protocol did not allow, and a longer step-up; the efficacy analysis models what happens if everyone follows the protocol36. In SYNCHRONIZE-1, weight fell 12.2% and 13.0% by the first and 15.3% and 16.6% by the second, versus 5.4% and 3.2% on placebo36.

The placebo group lost more weight than planned for, 5.4% versus the 2% to 3% assumed, and more than 16% of it reported using a prohibited GLP-1-based medicine6. Boehringer Ingelheim’s headline of up to 13.1% weight loss in SYNCHRONIZE-2, versus 3.1% on placebo, uses the efficacy analysis1.

Assigned dose versus dose reached

The phase 2 obesity trial grouped people by the dose assigned at the start, and by that measure weight fell by up to 14.9% on 4.8 mg8. Only 233 of 386 people (60.4%) completed the 46 weeks of treatment8. Zealand Pharma, which licensed survodutide to Boehringer Ingelheim, shows an analysis by the dose people reached at the end of treatment: up to 18.7% on 4.8 mg, in a group of 54 people, while 77 had been assigned to that dose813.

What the higher dose adds, and what it costs

In SYNCHRONIZE-1, weight fell 13.0% on 6.0 mg and 12.2% on 3.6 mg, while digestive side effects affected 89.7% and 80.9%3. In SYNCHRONIZE-2, in people with type 2 diabetes, weight fell 9.8% and 8.2%, while digestive side effects affected 77.7% and 72.8%4.

In the phase 2 MASH trial, the middle dose did best: MASH improved in 62% on 4.8 mg, versus 47% on 2.4 mg and 43% on 6.0 mg, and a curved (quadratic) dose-response fitted best9.

What about a missed dose?

Survodutide has no label, so there is no official rule for a missed dose1. Boehringer Ingelheim says its efficacy and safety have not been established1.

Why gray-market vials make doses unreliable

FDA says companies have illegally sold unapproved GLP-1 drugs, including survodutide, falsely labeled “for research purposes”, directly to consumers16. As of 7 October 2026, FDA’s warning-letter database listed two letters naming survodutide, dated 10 December 2024 and 24 August 2026171819.

Finnrick, an independent testing service, listed 27 survodutide tests dated 25 April 2025 to 23 April 2026: 13 passed, 13 failed and 1 was incomplete, as displayed on 7 October 20265. Its pass mark allows the measured dose to differ from the label by up to 35%5.

Questions people ask

How much survodutide should I take?

No dose is approved, because survodutide is not approved anywhere as of 7 October 202612. Phase 3 trials raised the dose step by step to 3.6 mg or 6.0 mg once a week34. Ask your prescriber about approved options.

What is the highest dose of survodutide tested?

6.0 mg once a week is the highest dose in the phase 2 and phase 3 trials on this page, used in SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-MASLD and the phase 2 MASH trial34910. The phase 1 trial’s published summary does not give its dose levels11.

Is survodutide 6 mg better than 3.6 mg?

In both phase 3 trials, weight fell more on 6.0 mg than on 3.6 mg at 76 weeks: 13.0% versus 12.2% in SYNCHRONIZE-1, against 5.4% on placebo, and 9.8% versus 8.2% in SYNCHRONIZE-2, against 3.9%34. Digestive side effects were also more common on 6.0 mg in both trials34.

How long did the survodutide step-up take in trials?

It varied: 20 weeks in the phase 2 obesity trial, and 24 weeks in both the phase 2 MASH trial and the phase 3 SYNCHRONIZE-MASLD trial, which raised the dose to 6.0 mg8910. The MASH trial’s authors called its 24-week step-up rapid, and Boehringer Ingelheim says current and upcoming trials allow more flexible step-ups19.

Go deeper

Sources

  1. 1Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Boehringer Ingelheim (GlobeNewswire), 1 Oct 2026. globenewswire.com
  2. 2Drugs@FDA via openFDA: search for active ingredient survodutide (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
  3. 3Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine, 20 Aug 2026. pubmed.ncbi.nlm.nih.gov
  4. 4Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes New England Journal of Medicine, 1 Oct 2026. pubmed.ncbi.nlm.nih.gov
  5. 5Survodutide Safety Testing Results & Vendor Ratings Finnrick, accessed 7 Oct 2026. finnrick.com
  6. 6Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss AJMC (The American Journal of Managed Care), 8 Jun 2026. ajmc.com
  7. 7Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia, Mar 2024. pubmed.ncbi.nlm.nih.gov
  8. 8Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial The Lancet Diabetes & Endocrinology, Mar 2024. pubmed.ncbi.nlm.nih.gov
  9. 9A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis New England Journal of Medicine, 25 Jul 2024. pubmed.ncbi.nlm.nih.gov
  10. 10Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nature Medicine, Aug 2026. pubmed.ncbi.nlm.nih.gov
  11. 11Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906 Diabetes, Obesity and Metabolism, Apr 2023. pubmed.ncbi.nlm.nih.gov
  12. 12BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Molecular Metabolism, Dec 2022. pubmed.ncbi.nlm.nih.gov
  13. 13Transforming the future of metabolic health: J.P. Morgan 44th Healthcare Conference 2026 Zealand Pharma A/S, 14 Jan 2026. zealandpharma.com
  14. 14Voluntary Announcement: First Dual GCG/GLP-1 Receptor Agonist Mazdutide Received Approval by the National Medical Products Administration for Chronic Weight Management Innovent Biologics, Inc. (HKEXnews), 27 Jun 2025. www1.hkexnews.hk
  15. 15Annual Report 2025 Innovent Biologics, Inc. (HKEXnews), 28 Apr 2026. www1.hkexnews.hk
  16. 16FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
  17. 17Warning Letters (database search for survodutide) U.S. Food and Drug Administration, accessed 7 Oct 2026. fda.gov
  18. 18Warning letter to Xcel Research LLC (MARCS-CMS 694608) U.S. Food and Drug Administration, 10 Dec 2024. fda.gov
  19. 19Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov

Not medical advice. Talk to a licensed clinician before using any drug. Report an error.